Skip to content

The Policy Vault

Methodology Why Contact

Coverage / Cigna / Brukinsa (zanubrutinib capsules and tablets) / Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma

Brukinsa (zanubrutinib capsules and tablets) — Cigna

Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma

Initial criteria

Patient age ≥ 18 years

Approval duration

1 year

Provenance

View official policy PDF

Plan: Cigna
Drug: Brukinsa (zanubrutinib capsules and tablets)
Indication: Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma
Last seen: 2025-10-15
Hash: f3b378afe904…

Disclaimer: Educational only. Coverage varies by employer group and formulary. Always verify with the plan.

Consult

Curious about trends across plans?

I can walk you through how this policy compares and share data-backed patterns. Short call, straight answers.

Email to start a quick consult What I cover (overview)

No commitments—just a brief conversation to see if it’s helpful.

The Policy Vault

Structured prior authorization and step-therapy criteria for commercial health plans. Built by pharmacists for healthcare professionals.

Disclaimer: Educational use only. Coverage varies by employer group and formulary. Always verify with the plan.

Product

Coverage Directory
Why Policy Vault
Methodology

Company

Contact
Press
Support

© 2025 The Policy Vault. Data sourced from official health plan documents.